På tilbagetrækningstidspunktet var det derfor CHMP' s opfattelse, at fordelene ved IPLEX ikke var godtgjort tilfredsstillende og ikke opvejede de fundne risici.
Therefore, at the time of the withdrawal, the CHMP’ s view was that the benefit of IPLEX had not been sufficiently demonstrated and did not outweigh the identified risks.